Ignite Creation Date:
2025-12-25 @ 4:03 AM
Ignite Modification Date:
2026-01-01 @ 6:11 PM
Study NCT ID:
NCT00259402
Status:
COMPLETED
Last Update Posted:
2009-12-07
First Post:
2005-11-28
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Oxaliplatin in Esophagus Cancer (Advanced) 1st Line
Sponsor:
Sanofi
Organization:
Study Overview
Official Title:
Phase II Open-label Single Arm Study of Oxaliplatin Combined With Cisplatin and 5FU in Advanced Esophagus Cancer Patients
Status:
COMPLETED
Status Verified Date:
2009-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
* To determine the activity and efficacy of the schema specified as dose regimen
* To determine the safety and tolerability of the oxaliplatin-cisplatin and 5FU
* To determine the safety and tolerability of the oxaliplatin-cisplatin and 5FU
Detailed Description:
None
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?: